PYPD
Polypid Ltd
NASDAQ · Pharmaceuticals
$4.52
+0.17 (+3.91%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 23.69M | 23.13M | 22.16M |
| Net Income | 4.47M | 4.40M | 4.69M |
| EPS | — | — | — |
| Profit Margin | 18.9% | 19.1% | 21.2% |
| Rev Growth | +11.0% | +7.8% | +15.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 4.60M | 5.17M | 4.28M |
| Total Equity | 56.27M | 54.67M | 47.29M |
| D/E Ratio | 0.08 | 0.09 | 0.09 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 8.95M | 8.70M | 7.31M |
| Free Cash Flow | 3.30M | 3.54M | 2.93M |